Weight-loss drugs fight it out

Share this article:

The battle of the bulge got bigger in the past week. First, Eisai announced Friday that it was adding 200 contract sales reps to tout the benefits of the prescription weight-loss drug Belviq. This means that 600 personnel will be able to talk to doctors about the benefits of the slimming drug, which, like competitor Qsymia by Vivus, works when accompanied by dietary and activity changes.

The enlarged sales force is expected to be active by July 1.

Then, Reuters reported Friday that generics maker Actavis wants to get into the Qsymia business and is using claims of invalid patents as part of its marketing application to make generics of the slimming drug, which has a 2020 patent expiration date attached to it.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.